{"id":"NCT01374516","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","officialTitle":"Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-08","primaryCompletion":"2014-11","completion":"2018-03-05","firstPosted":"2011-06-16","resultsPosted":"2019-03-27","lastUpdate":"2022-03-21"},"enrollment":20869,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever","Dengue Hemorrhagic Fever","Dengue"],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, dengue serotype 1, 2, 3, 4 virus","otherNames":["CYD Dengue Vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: (NaCl) 0.9% solution","otherNames":[]}],"arms":[{"label":"CYD Dengue Vaccine Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.\n\nPrimary Objective:\n\nTo assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four serotypes in children and adolescents aged 9 to 16 years at the time of inclusion.\n\nSecondary Objectives:\n\n* To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.\n* To describe the occurrence of hospitalized VCD cases and the occurrence of severe (clinically severe or as per World Health Organization (WHO) criteria) VCD cases, throughout the Surveillance Expansion Period (SEP) and throughout the trial (from Day 0 until the end of the study).\n* To describe the antibody response to each dengue serotype after Dose 2, after Dose 3, and 1 and 5 years after Dose 3.\n* To describe the occurrence of serious adverse events (SAEs), including SAEs of special interest in all participants throughout the trial period.","primaryOutcome":{"measure":"Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue Vaccine or a Placebo","timeFrame":"28 days and up to 13 months post-injection 3","effectByArm":[{"arm":"CYD Dengue Vaccine Group","deltaMin":176,"sd":null},{"arm":"Placebo Group","deltaMin":221,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":22,"countries":["Brazil","Colombia","Honduras","Mexico","Puerto Rico"]},"refs":{"pmids":["25365753","26214039","29408333","27007959","29897841","35659904","34219653","34003796","33822015","33212068","32040014","29300876","28871961","27459266","27418050"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1765,"n":13915},"commonTop":["Headache","Injection Site Pain","Myalgia","Malaise","Asthenia"]}}